Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort.

Autor: Anota A; Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France; Department of Human and Social Sciences, Centre Léon Bérard, Lyon, France; French National Platform Quality of Life and Cancer, Lyon, France. Electronic address: amelie.anota@lyon.unicancer.fr., Basset M; Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France., Charton E; Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France; Department of Human and Social Sciences, Centre Léon Bérard, Lyon, France., Bommier C; Hematology/Oncology, Université Paris Cité, Hôpital Saint Louis, Inserm U1153, Paris, France., Efficace F; Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center and Health Outcomes Research Unit, Rome, Italy., Dupuis J; Lymphoid Malignancies Unit, AP-HP, Henri Mondor University Hospital, Créteil, France., Cottone F; Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center and Health Outcomes Research Unit, Rome, Italy., Bouabdallah KK; Hematology and Cell Therapy Department, University Hospital of Bordeaux, Bordeaux, France., Mollevi C; Institute Desbrest of Epidemiology and Public Health, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, France., Ysebaert L; Institut universitaire du cancer de Toulouse Oncopole, Toulouse, France., Winter A; Biometrics Unit, Cancer Institute of Montpellier, University of Montpellier, Montpellier, France., Bijou F; Department of Hematology, Institut Bergonié, Bordeaux, France., Préau M; Inserm 1296, Université Lyon 2, Lyon, France., Chauchet A; Department of Hematology, Centre Hospitalier Universitaire de Besançon, Besançon, France., Bernier A; Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre Benite, France., Fornecker LM; Institut de Cancérologie Strasbourg Europe (ICANS) and University of Strasbourg, Strasbourg, France., Hafirassou H; Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre Benite, France., Carras S; Univ. Grenoble Alpes. Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309), University Hospital, Molecular Biology and Hematology departments, Grenoble, France., Lachenal F; Department of Hematology, Centre Hospitalier Pierre Oudot, Bourgoin-Jallieu, France., Lionne-Huyghe P; Department of Hematology, Centre Hospitalier d'Arras, Arras, France., Detourmignies L; Department of Hematology, Centre Hospitalier de Roubaix, Roubaix, France., Leyronnas C; Department of Hematology, Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France., Drénou B; Department Hematology, Groupe Hospitalier Mulhouse Sud Alsace, Mulhouse, France., Peyrou SLG; Registre des Hémopathies Malignes de la Gironde, Institut Bergonié, University of Bordeaux, Inserm, Team EPICENE, Bordeaux, France., Abraham J; Department of Hematology, Centre Hospitalier Universitaire de Limoges, Limoges, France., Monnereau A; Registre des Hémopathies Malignes de la Gironde, Institut Bergonié, University of Bordeaux, Inserm, Team EPICENE, Bordeaux, France., Fouillet L; Department of Hematology, Centre Hospitalier Universitaire de Saint Etienne, Saint Etienne, France., Morschhauser F; Department of Hematology, Universite de Lille, Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France., Rossi C; Department of Hematology, Centre Hospitalier Universitaire de Dijon Bourgogne, Dijon, France., Belot A; Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre Benite, France., Ghesquières H; Department of Hematology, Hopital Lyon Sud, Claude Bernard Lyon 1 University, Pierre Benite, France.
Jazyk: angličtina
Zdroj: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Sep; Vol. 208, pp. 114210. Date of Electronic Publication: 2024 Jul 04.
DOI: 10.1016/j.ejca.2024.114210
Abstrakt: Introduction: Considering the notable advances made in the treatment of lymphoma, assessment of health-related quality of life (HRQoL) of lymphoma patients has become a critical aspect to consider both in clinical research and routine practice. However, there is paucity of information about lymphoma specific HRQoL profile at diagnosis.
Patients and Methods: HRQoL at diagnosis was assessed for 3922 adult patients with newly diagnosed high-grade (HG) (n = 1994), low-grade (LG) (n = 1053) non-Hodgkin (NHL) and Hodgkin (HL) (n = 875) lymphomas included in REal world dAta in LYmphoma and Survival in Adults (REALYSA, NCT03869619), a prospective non-interventional multicentric cohort in France. Disease-specific HRQoL aspects were assessed with three validated EORTC questionnaires, namely, the QLQ-NHL-HG29, the QLQ-NHL-LG20 and the QLQ-HL27, for patients with NHL-HG, NHL-LG and HL, respectively.
Results: We confirmed the high-level of completion of these questionnaires in REALYSA cohort, ranging from 84 % for QLQ-HG29 to 88 % for QLQ-HL27. The proportion of patients with impaired global health status was as follows: T-cell NHL, 67 %; diffuse large B-cell (DLBCL), 62 %; Burkitt, 61 %; HL, 53 %; marginal zone, 49 %; mantle cell, 48 %; follicular, 47 %. Multivariable regression analyses for DLBCL, follicular and HL showed that gender, performance status and B symptoms were independently associated with all HRQoL dimensions. However, a variable effect of age and stage were observed among these three subtypes.
Conclusions: A comprehensive analysis was made describing the HRQoL profile of newly diagnosed patients with different types of lymphomas. Our data may help to enhance the interpretation of HRQoL results in future studies using the recently validated EORTC lymphoma specific questionnaires.
Competing Interests: Declaration of Competing Interest AA had a consultancy or advisory role for Astrazeneca and Gilead/LKite, outside the submitted work. FB had received support for attending meeting from AbbVie. FE had a consultancy or advisory role for AbbVie, Incyte, Syros, Novartis and JAZZ Pharmaceuticals, outside the submitted work. LY had consulting fees from Abbvie, AstraZeneca, Beigene, BMS/Celgene, Gilead/Kite, Janssen, Roche, honoraria from Abbvie, AstraZeneca, Beigene, BMS/Celgene, Gilead/Kite, Janssen, Roche, and support for attending meeting and/or travel from Abbvie, Beigene, Janssen. AC had consulting fees from AMGEN. All other authors declare no conflict of interest.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: